Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2013

View Archived Issues

Eliquis recommended by NICE in the U.K., launched in Japan

Scripps Research Institute presents new agents for HBV infection

Sunshine Biopharma gives update on Adva-27a testing

Euroscreen receives grant to develop drugs for neurodegenerative diseases

Xellia enters collaboration to combat multidrug-resistant bacteria

Omalizumab evaluated in phase III trial for CIU/CSU

Taiho Pharmaceutical seeks Japanese approval for TAS-102 in recurrent colorectal cancer

Clinical results presented for ragweed AIT in patients with allergic rhinoconjunctivitis

Mapp Biopharmaceutical presents new antibodies against category B biothreats

hiPSCs used to generate cells for treating myelin loss

Boehringer Ingelheim Pharma patents new gamma-secretase modulators

Janssen R&D Ireland patents novel agents for infections

Phosphodiesterase PDE4 inhibitors synthesized at Amakem

Aciex Therapeutics and Portola Pharmaceuticals to develop ophthalmic drugs

Integrated BioTherapeutics begins first-in-human trial of STEBVax

Roche expands access to clinical trial data

FDA stops pediatric trials of Sensipar

XBiotech launches biosimilars business

Io Therapeutics collaborates with the Michael J. Fox Foundation

Clinical trial data presented for taliglucerase alfa in patients with Gaucher's disease

FDA accepts Stedesa NDA resubmission for review

Sanofi launches Dellegra combination tablets in Japan

Phase I clinical results reported for anthrax vaccine AV-7909

Boehringer Ingelheim commences pivotal trial of volasertib in acute myeloid leukemia

Japanese authorities broaden indication for Lyrica to neuropathic pain

Benet Tablets 75 mg available in Japan

Rare Disease Day being celebrated around the world

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...